Clinical Trial

Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the impact of prostate-specific membrane antigen/positron emission tomography (PSMA/PET)-informed magnetic resonance (MR)-guided radiation therapy on serious toxicity outcomes in patients with biopsy-proven locally radiorecurrent prostate cancer. The primary aim is to evaluate the safety of delivering MR-Linac-guided stereotactic body radiotherapy (SBRT) after prior prostate external beam radiotherapy for recurrent disease, and assess urinary toxicity outcomes at 2 years.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-20.
Trial Details
NCT Number NCT07142967
Lead Sponsor NYU Langone Health
Conditions Intraprostatic Prostate Cancer
Enrollment 28 participants
Start Date 2025-08-15
Primary Completion 2028-08-01 (estimated)
Study Completion 2030-08-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-10